

PT Treatment of victims of bee or scorpion stings or plant or bacterial

PT toxins - by admin. of lethal toxin-neutralising factor or its
 XX N-terminal peptide

PS Claim 7; Column 9; 9pp; English.

XX The present sequence is from the N-terminus of a 68 kD protein
 CC purified from the serum of the opossum *Didelphis virginiana*. The
 CC full-length protein is a lethal toxin neutralising factor (LTNF).
 CC The use of purified LTNF or of the chemically synthesised 15mer
 CC N-terminal peptide for treating victims of bee stings, scorpion
 CC stings and bacterial or plant toxins is claimed. The patent
 CC disclosure does not provide any evidence for neutralising activity
 CC against these various toxins. There is evidence of significant
 CC neutralising activity of the opossum LTNF and the 15mer peptide
 CC against venom from snakes of the families Crotalidae, Elapidae,
 CC Hydroliidae and Viperidae.

XX Sequence 15 AA;

Query Match 100.0%; Score 84; DB 18; Length 15;
 Best Local Similarity 100.0%; Pred. No. 8.7e-07;
 Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 LKAMDPTPPLWKTE 15

DB 1 LKAMDPTPPLWKTE 15

RESULT 2

AAW53841
 ID AAW53841 standard; peptide; 15 AA.

XX AC AAW53841;

XX DT 08-JUL-1998 (first entry)

XX DE N-terminus of opossum LTNF.

XX LTNF; lethal toxin neutralising factor; opossum; envenomation; therapy;
 KW anti-haemorrhagic protein; Elapidae; Viperidae; sea snake; snake bite;
 KW sepsis; allergy; bee sting; scorpion sting; plant toxin; bacterial toxin;
 KW histamine reaction treatment.

XX OS *Didelphis virginiana*.

XX PN US744449-A.

XX PD 28-APR-1998.

XX PF 03-JUN-1996; 96US-0657163.

XX PR 03-JUN-1996; 96US-0657163.

XX PR 10-MAY-1993; 93US-0058387.

XX PR 22-SEP-1994; 94US-0310340.

XX PA (LIPP/) LIPPS B V.

XX PA (LIPP/) LIPPS F W.

XX PI Lipps BV, Lipps FW;

XX DR WPI; 1998-271108/24.

XX Lethal Toxin Neutralising Factor peptide from opossum - can
 PT neutralise venom(s) from all major families of poisonous snakes

XX Claim 1; Column 11; 11pp; English.

XX This sequence represents the peptide of the invention. It is a Lethal
 CC Toxin Neutralising Factor (LTNF) moiety from a 68 kDa anti-haemorrhagic
 CC protein derived from an opossum. The peptide can be used in a method for
 CC treating a victim of envenomation from a poisonous snake, preferably a
 CC poisonous snake from the family of Elapidae, Viperidae or sea snake.
 CC It is useful for the treatment of snake bites, sepsis, allergies caused

CC by the environment and treatment of bee or scorpion stings or toxicities
 CC caused by plant or bacterial toxins. The peptide can also be used in
 CC histamine reaction treatment. The peptide can be used in envenomation
 CC treatment for a variety of snakes without prior identification of the
 CC snake. Being short it can be synthetically prepared rather than the
 CC current production in horses, where some people can show hypersensitivity
 CC to horse proteins.

XX Sequence 15 AA;

Query Match 100.0%; Score 84; DB 19; Length 15;

Best Local Similarity 100.0%; Pred. No. 8.7e-07;
 Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 LKAMDPTPPLWKTE 15

DB 1 LKAMDPTPPLWKTE 15

RESULT 3

AAW53843

ID AAW53843 standard; peptide; 10 AA.

XX AC AAW53843;

XX DT 08-JUL-1998 (first entry)

XX DE N-terminus of opossum LTNF.

XX LTNF; lethal toxin neutralising factor; opossum; envenomation; therapy;
 KW anti-haemorrhagic protein; Elapidae; Viperidae; sea snake; snake bite;
 KW sepsis; allergy; bee sting; scorpion sting; plant toxin; bacterial toxin;
 KW histamine reaction treatment.

XX OS *Didelphis virginiana*.

XX PN US744449-A.

XX PD 28-APR-1998.

XX PF 03-JUN-1996; 96US-0657163.

XX PR 03-JUN-1996; 96US-0657163.

XX PR 10-MAY-1993; 93US-0058387.

XX PR 22-SEP-1994; 94US-0310340.

XX PA (LIPP/) LIPPS B V.

XX PA (LIPP/) LIPPS F W.

XX PI Lipps BV, Lipps FW;

XX DR WPI; 1998-271108/24.

XX Lethal Toxin Neutralising Factor peptide from opossum - can
 PT neutralise venom(s) from all major families of poisonous snakes

XX Claim 7; Column 11; 11pp; English.

XX This sequence represents the peptide of the invention. It is a Lethal
 CC Toxin Neutralising Factor (LTNF) moiety from a 68 kDa anti-haemorrhagic
 CC protein derived from an opossum. The peptide can be used in a method for
 CC treating a victim of envenomation from a poisonous snake, preferably a
 CC poisonous snake from the family of Elapidae, Viperidae or sea snake.
 CC It is useful for the treatment of snake bites, sepsis, allergies caused
 CC by the environment and treatment of bee or scorpion stings or toxicities
 CC caused by plant or bacterial toxins. The peptide can also be used in
 CC histamine reaction treatment. The peptide can be used in envenomation
 CC treatment for a variety of snakes without prior identification of the
 CC snake. Being short it can be synthetically prepared rather than the
 CC current production in horses, where some people can show hypersensitivity
 CC to horse proteins.

XX Sequence 10 AA;

Query Match 64.3%; Score 54; DB 19; Length 10;
 Best Local Similarity 100.0%; Pred. No. 0.033;
 Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 LKAMDPTPPL 10
 | | | | | | | | | |
 DB 1 LKAMDPTPPL 10

RESULT 4
 ABG18144
 ID ABG18144 standard; Protein; 303 AA.

XX AC ABG18144;

XX DT 18-FEB-2002 (first entry)

XX DE Novel human diagnostic protein #18135.

XX KW Human; chromosome mapping; gene mapping; gene therapy; forensic;
 KW food supplement; medical imaging; diagnostic; genetic disorder.

XX OS Homo sapiens.

XX PN WO200175067-A2.

XX PD 11-OCT-2001.

XX PF 30-MAR-2001; 2001WO-US08631.

XX PR 31-MAR-2000; 2000US-0540217.

XX PR 23-AUG-2000; 2000US-0649167.

XX PA (HYSE-) HYSEQ INC.

XX PI Drmanac RT, Liu C, Tang YT;

XX DR WPI: 2001-639362/73.

XX DR N-PSDB; AAS82331.

XX PT New isolated polynucleotide and encoded polypeptides, useful in
 PT diagnostics, forensics, gene mapping, identification of mutations
 PT responsible for genetic disorders or other traits and to assess
 PT biodiversity

XX PS Claim 20; SEQ ID NO 48503; 103pp; English.

XX CC The invention relates to isolated polynucleotide (I) and
 CC polypeptide (II) sequences. (I) is useful as hybridisation probes,
 CC polymerase chain reaction (PCR) primers, oligomers, and for chromosome
 CC and gene mapping, and in recombinant production of (II). The
 CC polynucleotides are also used in diagnostics as expressed sequence tags
 CC for identifying expressed genes. (I) is useful in gene therapy techniques
 CC to restore normal activity of (II) or to treat disease states involving
 CC quantitating a polypeptide in tissue, as molecular weight markers and as
 CC a food supplement. (II) and its binding partners are useful in medical
 CC imaging of sites expressing (II). (I) and (II) are useful for treating
 CC disorders involving aberrant protein expression or biological activity.
 CC The polypeptide and polynucleotide sequences have applications in
 CC diagnostics, forensics, gene mapping, identification of mutations
 CC responsible for genetic disorders or other traits to assess biodiversity
 CC and to produce other types of data and products dependent on DNA and
 CC amino acid sequences. ABG00010-ABG30377 represent novel human
 CC diagnostic amino acid sequences of the invention.

XX CC Note: The sequence data for this patent did not appear in the printed
 CC specification, but was obtained in electronic format directly from WIPO
 CC at ftp.wipo.int/pub/published_pct_sequences.

XX SQ Sequence 303 AA;

Query Match 56.0%; Score 47; DB 22; Length 303;

Best Local Similarity 42.9%; Pred. No. 15;
 Matches 6; Conservative 4; Mismatches 4; Indels 0; Gaps 0;

QY 2 KAMDPTPPLWKTE 15
 : | | | | | :
 DB 39 EASDPVPYWRVRLQ 52

RESULT 5

AAAY74718

ID AAY74718 standard; Protein; 267 AA.

XX AC AAY74718;

XX DT 21-MAR-2000 (first entry)

XX DE Neisseria meningitidis ORF 241 protein sequence SEQ ID NO:910.

XX KW Neisseria meningitidis; Neisseria gonorrhoeae; antigen; vaccine;
 KW antigenic; diagnosis; immunogenic; infection; meningitis; septicaemia;
 KW antibacterial; gene therapy.

XX OS Neisseria meningitidis.

XX PN WO9957280-A2.

XX PD 11-NOV-1999.

XX PF 30-APR-1999; 99WO-US09346.

XX PR 01-MAY-1998; 98US-0083758.

XX PR 31-JUL-1998; 98US-0094889.

XX PR 02-SEP-1998; 98US-0098994.

XX PR 02-SEP-1998; 98US-0099062.

XX PR 09-OCT-1998; 98US-0103749.

XX PR 09-OCT-1998; 98US-0103794.

XX PR 09-OCT-1998; 98US-0103796.

XX PR 25-FEB-1999; 99US-0121528.

XX PA (CHIR) CHIRON CORP.

XX FR (GENO-) INST GENOMIC RES.

XX PI Fraser C, Galeotti C, Grandi G, Hickey E, Masignani V, Mora M;

XX PI Petersen J, Pizsa M, Rappuoli R, Ratti G, Scalato E, Scarselli M;

XX PI Tettelin H, Venter JC;

XX DR WPI: 2000-062150/05.

XX DR N-PSDB; AAZ53480.

XX PT Novel Neisserial polypeptides predicted to be useful antigens for
 PT vaccines and diagnostics

XX PS Claim 2; Page 553; 1453pp; English.

XX CC AAZ53015 to AAZ54536, AAZ54577 to AAZ54615, and AAY74253 to AAY75941
 CC represent novel Neisseria meningitidis and N. gonorrhoeae polynucleotides
 CC and polypeptides, AAZ54537 to AAZ54576 and AAZ54616 to AAZ5473 represent
 CC PCR primers used in the exemplification of the present invention. The
 CC polypeptides, the polynucleotides, antibodies and compositions of
 CC the invention can be used as vaccines, as diagnostic reagents, and as
 CC immunogenic compositions. The polypeptides can be used in the
 CC manufacture of medicaments for treating or preventing infection due to
 CC Neisserial bacteria (e.g. meningitis and septicaemia), to detect the
 CC presence of Neisseria bacteria, or to raise antibodies. They may also
 CC be used to screen for agonists or antagonists, which may themselves
 CC have use as antibacterial agents. The polynucleotides of the invention
 CC may also be used in gene therapy protocols.

XX SQ Sequence 267 AA;

Query Match 54.8%; Score 46; DB 21; Length 267;

Best Local Similarity 58.3%; Pred. No. 19;

Matches 7; Conservative 2; Mismatches 3; Indels 0; Gaps 0;

QY 3 AMDPTPLWIKT 14
I
Db 9 AKHPTPTWLQT 20

RESULT 6
AA74721
ID AAY74721 standard; Protein: 267 AA.
XX
AC AAY74721;
XX
DT 21-MAR-2000 (first entry)
XX
DE Neisseria meningitidis ORF 241 protein sequence SEQ ID NO:916.
XX
KW Neisseria meningitidis; Neisseria gonorrhoeae; antigen; vaccine;
KW antigenic; diagnosis; immunogenic; infection; meningitis; septicaemia;
KW antibacterial; gene therapy.
XX
OS Neisseria meningitidis.
XX
PN WO9957280-A2.
XX
PD 11-NOV-1999.
XX
PF 30-APR-1999; 99WO-US09346.
XX
PR 01-MAY-1998; 98US-0083758.
PR 31-JUL-1998; 98US-0094869.
PR 02-SEP-1998; 98US-0098994.
PR 02-SEP-1998; 98US-0099062.
PR 09-OCT-1998; 98US-0103749.
PR 09-OCT-1998; 98US-0103794.
PR 09-OCT-1998; 98US-0103796.
PR 25-FEB-1999; 99US-0121528.
XX
PA (CHIR) CHIRON CORP.
PA (GENO-) INST GENOMIC RES.
PI Fraser C, Galeotti C, Grandi G, Hickey E, Massignani V, Mora M;
PI Petersen J, Piza M, Rappuoli R, Ratti G, Scalato E, Scarselli M;
PI Tettelin H, Venter JC;
XX
DR WPI; 2000-062150/05.
DR N-PSDB; AA53483.
XX
PT Novel Neisserial polypeptides predicted to be useful antigens for
PT vaccines and diagnostics
XX
PS Claim 2; Page 555; 1453pp; English.
XX
CC AA53015 to AA54536, AA54577 to AA54615, and AAY74253 to AAY75941
CC represent novel Neisseria meningitidis and N. gonorrhoeae polynucleotides
CC and polypeptides. AA54537 to AA54576 and AA54616 to AA54573 represent
CC PCR primers used in the exemplification of the present invention. The
CC polypeptides, the polynucleotides, antibodies and compositions of
CC the invention can be used as vaccines, as diagnostic reagents, and as
CC immunogenic compositions. The polypeptides can be used in the
CC manufacture of medicaments for treating or preventing infection due to
CC Neisserial bacteria (e.g. meningitis and septicaemia), to detect the
CC presence of Neisseria bacteria, or to raise antibodies. They may also
CC be used to screen for agonists or antagonists, which may themselves
CC have use as antibacterial agents. The polynucleotides of the invention
CC may also be used in gene therapy protocols.
XX
SQ Sequence 267 AA;

Query Match 54.8%; Score 46; DB 21; Length 267;
Best Local Similarity 58.3%; Pred. NO. 19;
Matches 7; Conservative 2; Mismatches 3; Indels 0; Gaps 0;

QY 3 AMDPTPLWIKT 14

Db 9 AKHPTPTWLQT 20
I

RESULT 7
ABBS9797
ID ABB59797 standard; Protein: 729 AA.
XX
AC ABB59797;
XX
DT 26-MAR-2002 (first entry)
XX
DE Drosophila melanogaster polypeptide SEQ ID NO 6183.
XX
KW Drosophila; developmental biology; cell signalling; insecticide;
KW pharmaceutical.
XX
OS Drosophila melanogaster.
XX
PN WO200171042-A2.
XX
PD 27-SEP-2001.
XX
PF 23-MAR-2001; 2001WO-US09231.
XX
PR 23-MAR-2000; 2000US-191637P.
PR 11-JUL-2000; 2000US-0614150.
XX
PA (PEKE) PE CORP NY.
XX
PI Venter JC, Adams M, Li PWD, Myers EW;
XX
DR WPI; 2001-656860/75.
XX
DR N-PSDB; ABL03900.
XX
PT New isolated nucleic acid detection reagent for detecting 1000 or more
PT genes from Drosophila and for elucidating cell signalling and cell-cell
PT interactions
XX
PS Disclosure; SEQ ID NO 6183; 21pp + Sequence Listing; English.
XX
CC The invention relates to an isolated nucleic acid detection reagent
CC capable of detecting 1000 or more genes from Drosophila. The invention is
CC useful in developmental biology and in elucidating cell signalling and
CC cell-cell interactions in higher eukaryotes for the development of
CC insecticides, therapeutics and pharmaceutical drugs. The invention
CC discloses genomic DNA sequences (ABL16176-ABL30511), expressed DNA
CC sequences (ABL01840-ABL16175) and the encoded proteins
CC (ABB57737-ABB72072).
XX
CC The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences.
XX
SQ Sequence 729 AA;

Query Match 54.8%; Score 46; DB 22; Length 729;
Best Local Similarity 57.1%; Pred. NO. 55;
Matches 8; Conservative 2; Mismatches 4; Indels 0; Gaps 0;

QY 1 LKAMDPTPLWIKT 14
I
Db 689 LKAQNSTPLWLNT 702

RESULT 8
AAR56496
ID AAR56496 standard; Protein: 1189 AA.
XX
AC AAR56496;
XX
DT 23-MAR-1995 (first entry)
XX
DE TATA-binding protein-associated factor dTAF150.

XX TATA-binding protein associated factor; dTAFI50; screening;
 KW diagnostic; therapeutic; gene transcription regulation.
 XX Drosophila.

XX Key Location/Qualifiers
 PH Misc-difference 923
 FT /note= "Val or Leu"
 FT Misc-difference 1106
 FT /note= "Arg, Pro or His"
 FT Misc-difference 1172
 FT /note= "STOP"
 FT Misc-difference 1176
 FT /note= "STOP"

XX W09417087-A.
 XX
 XX 04-AUG-1994.
 XX
 XX 28-JAN-1994; 94WO-US01114.
 XX
 XX 28-JAN-1993; 93US-0013412.
 XX 30-JUN-1993; 93US-0087119.
 XX (REGC) UNIV CALIFORNIA.
 XX
 XX Comai L, Dynlacht BD, Hoey T, Ruppert S, Tanese N;
 PI Tjian R, Wang E, Weinzierl ROJ;
 XX WPI; 1994-264019/32.
 DR N-PSDB; AAQ70733.
 XX
 XX TATA-binding protein associated protein factors - and
 PT corresponding nucleotide sequence and deriv. antibodies, useful
 PT in screening, diagnostics and therapeutics
 XX
 XX Disclosure; Page 156; 180pp; English.
 XX
 XX The TATA-binding protein associated factor hTAFI50 (including
 CC specific antibodies and fusion products) are used in drug screening,
 CC diagnostics and therapeutics. They are used in the development of
 CC specific biochemical assays for screening compounds that agonise or
 CC antagonise selected transcription factors involved in regulating
 CC gene expression associated with human pathology.
 XX
 XX Sequence 1189 AA;
 SQ
 Query Match 54.8%; Score 46; DB 15; Length 1189;
 Best Local Similarity 53.3%; Pred. No. 92;
 Matches 8; Conservative 3; Mismatches 4; Indels 0; Gaps 0;

QY 1 LKAMDPTPLWKTE 15
 | | | | : | | | :
 Db 589 LSAMDDSPVLWIRLD 603

RESULT 9
 AAW06086
 ID AAW06086 standard; Protein; 1213 AA.
 XX
 AC AAW06086;
 XX
 XX 27-JAN-1997 (first entry)
 DT
 XX Drosophila TATA-binding protein associated factor dTAFI150 protein.
 DE
 XX Drosophila; TATA-binding protein; TBP associated factor; TFIID;
 KW RNA polymerase II; transcription; messenger RNA; nuclear fraction;
 KW holoenzyme; lambda-gt11; expression library.
 XX
 OS Drosophila melanogaster.
 XX

PN US534410-A.
 XX
 XX 09-JUL-1996.
 XX
 XX 28-JAN-1993; 93US-0013412.
 XX
 XX 28-JAN-1994; 94US-0188582.
 PR 28-JAN-1993; 93US-0013412.
 PR 30-JUN-1993; 93US-0087119.
 XX
 XX (REGC) UNIV CALIFORNIA.
 XX
 XX Comai L, Dynlacht BD, Hoey T, Ruppert S, Tanese N;
 PI Tjian R, Wang E, Weinzierl ROJ;
 XX WPI; 1996-333245/33.
 DR N-PSDB; AAT43219.
 XX
 XX Screen for cpds. that bind human TATA-binding protein associated
 PT factor - by testing ability to bind to polypeptide fragments of the
 PT factor, useful as (ant)agonists of transcription factors involved in
 PT disease.
 XX
 XX Examples; Column 123-132; 86pp; English.
 XX
 XX This is the amino acid sequence of the Drosophila TATA-binding protein
 CC (TBP) associated factor (TAF) designated TAFI160. The protein is a
 CC component of the TFIID fraction required for reconstituting RNA
 CC polymerase II in vitro transcription activity. The encoded protein
 CC has an estimated mol. wt. of 60 kD by SDS-PAGE.
 CC The invention relates to purified proteins involved in transcription
 CC by RNA polymerase II, the RNA polymerase which transcribes messenger
 CC RNA. RNA polymerase II transcription proceeds in vitro upon addition
 CC of several nuclear fractions designated TFIIA, B, D, E, F, H, I and J
 CC to RNA polymerase II holoenzyme. Fraction TFIID has been shown to
 CC contain a TBP and other TAFs. Purification of TFIID and separation of
 CC its components reveals 7 proteins ranging in size from 30-250 kD.
 CC Serum raised against the TFIID fraction allowed cloning of the corresp.
 CC genes from lambda-gt11 expression libraries.
 XX
 XX Sequence 1213 AA;
 SQ
 Query Match 54.8%; Score 46; DB 17; Length 1213;
 Best Local Similarity 53.3%; Pred. No. 94;
 Matches 8; Conservative 3; Mismatches 4; Indels 0; Gaps 0;

QY 1 LKAMDPTPLWKTE 15
 | | | | : | | | :
 Db 620 LSAMDDSPVLWIRLD 634

RESULT 10
 AAW25029
 ID AAW25029 standard; Protein; 1213 AA.
 XX
 AC AAW25029;
 XX
 XX 08-OCT-1997 (first entry)
 DT
 XX TATA-binding protein associated factor, dTAFI150.
 DE
 XX TATA-binding protein associated factor; TAF; nuclear protein;
 KW RNA polymerase transcription; TATA-binding protein; TBP;
 KW initiation.
 KW
 XX Drosophila sp.
 OS
 XX US5637686-A.
 PN
 XX 10-JUN-1997.
 PD
 XX 28-JAN-1993; 93US-0013412.
 PF
 XX

PR 28-JAN-1994; 94US-0198582.
 PR 28-JAN-1993; 93US-0013412.
 PR 30-JUN-1993; 93US-0087119.
 PR 09-MAY-1996; 96US-0646715.
 XX
 XX (REGC) UNIV CALIFORNIA.
 XX
 XX Conai L, Dynlact BD, Hoey T, Ruppert S, Tanese N;
 PI Tjian R, Wang E, Weinzierl ROJ;
 XX
 XX WPI; 1997-319113/29.
 DR N-PSDB; AAT79605.
 XX
 XX Nucleic acids encoding human TATA-binding protein associated factor
 PT (TAF) peptide(s) - for production of recombinant peptide(s), used
 PT for modulating transcription of TAFs
 XX
 XX Example 1; Column 131-138; 86pp; English.
 XX
 XX AAW25029 represents TATA-binding protein associated factor (TAF)
 CC polypeptide, dTAFII150 (mol. weight 150KD). TAF peptides derived
 CC from dTAFII30 alpha, dTAFII30 beta, dTAFII40, dTAFII60, dTAFII80,
 CC dTAFII110, dTAFII150, and dTAFII250, their human equivalents and
 CC nucleic acids encoding them, are used to modulate transcription,
 CC including transcription initiation. TAFs are nuclear proteins involved
 CC in RNA polymerase I, II and III transcription. The peptides act by
 CC binding to a different TAF, an activator, or TBP (TATA-binding protein)
 CC or competitively inhibiting association of a TAF domain with another
 CC compound, typically a protein like TBP or another TAF, an activator,
 CC or DNA.
 XX
 XX Sequence 1213 AA;
 SQ
 Query Match 54.8%; Score 46; DB 18; Length 1213;
 Best Local Similarity 53.3%; Pred. No. 94;
 Matches 8; Conservative 3; Mismatches 4; Indels 0; Gaps 0;
 QY 1 LKAMDPTPPLWKYTE 15
 | | | | : | | | :
 Db 620 LSAMDSPVLWRLD 634
 RESULT 11
 ABB62618
 ID ABB62618 standard; Protein; 1219 AA.
 AC ABB62618;
 XX
 XX 26-MAR-2002 (first entry)
 DT
 DE Drosophila melanogaster polypeptide SEQ ID NO 14646.
 XX
 XX Drosophila; developmental biology; cell signalling; insecticide;
 KW pharmaceutical.
 KW
 XX Drosophila melanogaster.
 OS
 XX WO200171042-A2.
 PN
 XX 27-SEP-2001.
 PD
 XX
 XX 23-MAR-2001; 2001WO-US09231.
 PF
 XX
 XX 23-MAR-2000; 2000US-191637P.
 PR
 XX 11-JUL-2000; 2000US-0614150.
 PR
 XX (PEKE) PE CORP NY.
 PA
 XX Venter JC, Adams M, Li PWD, Myers EW;
 PI
 XX WPI; 2001-656860/75.
 DR
 XX N-PSDB; ABL06721.
 DR
 XX

PT New isolated nucleic acid detection reagent for detecting 1000 or more
 PT genes from Drosophila and for elucidating cell signalling and cell-cell
 PT interactions -
 XX
 XX Disclosure; SEQ ID NO 14646; 21pp + Sequence Listing; English.
 XX
 XX The invention relates to an isolated nucleic acid detection reagent
 CC capable of detecting 1000 or more genes from Drosophila. The invention is
 CC useful in developmental biology and in elucidating cell signalling and
 CC cell-cell interactions in higher eukaryotes for the development of
 CC insecticides, therapeutics and pharmaceutical drugs. The invention
 CC discloses genomic DNA sequences (ABLI16176-ABLI30511), expressed DNA
 CC sequences (ABLI01840-ABLI16175) and the encoded proteins
 CC (ABB57737-ABB72072).
 CC The sequence data for this patent did not form part of the printed
 CC specification, but was obtained in electronic format directly from WIPO
 CC at ftp.wipo.int/pub/published_pct_sequences.
 XX
 XX Sequence 1219 AA;
 SQ
 Query Match 54.8%; Score 46; DB 22; Length 1219;
 Best Local Similarity 53.3%; Pred. No. 95;
 Matches 8; Conservative 3; Mismatches 4; Indels 0; Gaps 0;
 QY 1 LKAMDPTPPLWKYTE 15
 | | | | : | | | :
 Db 618 LSAMDSPVLWRLD 632
 RESULT 12
 AAY74720
 ID AAY74720 standard; Protein; 267 AA.
 AC AAY74720;
 XX
 XX 21-MAR-2000 (first entry)
 DT
 XX
 DE Neisseria meningitidis ORF 241 protein sequence SEQ ID NO:914.
 XX
 XX Neisseria meningitidis; Neisseria gonorrhoeae; antigen; vaccine;
 KW antigenic; diagnosis; immunogenic; infection; meningitis; septicaemia;
 KW antibacterial; gene therapy.
 XX
 XX Neisseria meningitidis.
 OS
 XX WO9957280-A2.
 PN
 XX 11-NOV-1999.
 PD
 XX 30-APR-1999; 99WO-US09346.
 PF
 XX 01-MAY-1998; 98US-0083758.
 PR 31-JUL-1998; 98US-0094869.
 PR 02-SEP-1998; 98US-0098994.
 PR 02-SEP-1998; 98US-0099062.
 PR 09-OCT-1998; 98US-0103749.
 PR 09-OCT-1998; 98US-0103794.
 PR 09-OCT-1998; 98US-0103796.
 PR 25-FEB-1999; 99US-0121528.
 XX
 XX (CHIR) CHIRON CORP.
 PA (GENO-) INST GENOMIC RES.
 XX
 XX Fraser C, Galeotti C, Grandi G, Hickey E, Masignani V, Mora M;
 PI Petersen J, Pizsa M, Rappuoli R, Ratti G, Scalato E, Scarselli M;
 PI Tettelin H, Venter JC;
 XX
 XX WPI; 2000-062150/05.
 DR N-PSDB; AAZ53482.
 DR
 XX Novel Neisserial polypeptides predicted to be useful antigens for
 PT vaccines and diagnostics -
 XX

PS Claim 2; Page 554; 1453pp; English.

CC AAZ53015 to AAZ54536, AAZ54577 to AAZ54615, and AAZ74253 to AAZ75941
 CC represent novel *Neisseria meningitidis* and *N. gonorrhoeae* polynucleotides
 CC and polypeptides. AAZ54537 to AAZ54576 and AAZ54616 to AAZ5473 represent
 CC PCR primers used in the exemplification of the present inventions. The
 CC polypeptides, the polynucleotides, antibodies and compositions of
 CC the invention can be used as vaccines, as diagnostic reagents, and as
 CC immunogenic compositions. The polypeptides can be used in the
 CC manufacture of medicaments for treating or preventing infection due to
 CC *Neisseria meningitidis* (e.g. meningitis and septicemia), to detect the
 CC presence of *Neisseria meningitidis*, or to raise antibodies. They may also
 CC be used to screen for agonists or antagonists, which may themselves
 CC have use as antibacterial agents. The polynucleotides of the invention
 CC may also be used in gene therapy protocols.

XX SQ Sequence 267 AA;

Query Match 53.6%; Score 45; DB 21; Length 267;
 Best Local Similarity 58.3%; Pred. No. 28;
 Matches 7; Conservative 2; Mismatches 3; Indels 0; Gaps 0;

QY 3 AMDPTPLWIKT 14
 | | | | | : : :
 Db 9 ANPPTPTWLQT 20

RESULT 13

ABB42105
 ID ABB42105 standard; Peptide; 37 AA.

AC ABB42105;

DT 04-FEB-2002 (first entry)

DE Peptide #9611 encoded by human foetal liver single exon probe.

KW Human; foetal liver; gene expression; single exon nucleic acid probe.

XX Homo sapiens.

XX WO200157277-A2.

XX 09-AUG-2001.

XX 30-JAN-2001; 2001WO-US00669.

XX 04-FEB-2000; 2000US-0180312.

XX 26-MAY-2000; 2000US-0207456.

XX 30-JUN-2000; 2000US-0608408.

XX 03-AUG-2000; 2000US-0632366.

XX 21-SEP-2000; 2000US-0234687.

XX 27-SEP-2000; 2000US-0236359.

XX 04-OCT-2000; 2000GB-0024263.

XX (MOLE-) MOLECULAR DYNAMICS INC.

XX Penn SG, Hanzel DK, Chen W, Rank DR;

XX WPI; 2001-483447/52.

XX Human genome-derived single exon nucleic acid probes useful for

XX analyzing gene expression in human foetal liver -

XX Claim 27; SEQ ID NO 34740; 639pp + sequence listing; English.

XX The invention relates to a single exon nucleic acid probe for

XX measuring human gene expression in a sample derived from human foetal

XX liver. The single exon nucleic acid probes may be used for predicting,

XX measuring and displaying gene expression in samples derived from human

XX foetal liver. The present sequence is a peptide encoded by a single exon

XX nucleic acid probe of the invention.

CC printed specification, but was obtained in electronic format directly
 CC from WIPO at ftp.wipo.int/pub/published_pct_sequences.

XX SQ Sequence 37 AA;

Query Match 52.4%; Score 44; DB 22; Length 37;
 Best Local Similarity 46.2%; Pred. No. 5;
 Matches 6; Conservative 4; Mismatches 3; Indels 0; Gaps 0;

QY 2 KAMDPTPLWIKT 14
 | | | | | : : :
 Db 5 KSMGPAPRWMS 17

RESULT 14

AAM62985
 ID AAM62985 standard; Protein; 37 AA.

XX AC AAM62985;

XX DT 05-NOV-2001 (first entry)

XX Human brain expressed single exon probe encoded protein SEQ ID NO: 35090.

XX Human; brain expressed exon; gene expression analysis; probe;

KW microarray; Alzheimer's disease; multiple sclerosis; schizophrenia;

KW epilepsy; cancer.

XX Homo sapiens.

XX WO200157275-A2.

XX 09-AUG-2001.

XX 30-JAN-2001; 2001WO-US00667.

XX 04-FEB-2000; 2000US-0180312.

XX 26-MAY-2000; 2000US-0207456.

XX 30-JUN-2000; 2000US-0608408.

XX 03-AUG-2000; 2000US-0632366.

XX 21-SEP-2000; 2000US-0234687.

XX 27-SEP-2000; 2000US-0236359.

XX 04-OCT-2000; 2000GB-0024263.

XX (MOLE-) MOLECULAR DYNAMICS INC.

XX Penn SG, Hanzel DK, Chen W, Rank DR;

XX WPI; 2001-483446/52.

XX Single exon nucleic acid probes for analyzing gene expression in human

XX brains -

XX Example 4; SEQ ID NO: 35090; 650pp + Sequence Listing; English.

XX The present invention provides a number of single exon nucleic acid

XX probes which are derived from genomic sequences expressed in the human

XX brain. They can be used to measure gene expression in brain cell samples,

XX which may enable the diagnosis and improved treatment of nervous system

XX diseases such as Alzheimer's disease, multiple sclerosis, schizophrenia,

XX epilepsy and cancers. The present sequence is a protein encoded by one of

XX the probes of the invention.

XX SQ Sequence 37 AA;

Query Match 52.4%; Score 44; DB 22; Length 37;
 Best Local Similarity 46.2%; Pred. No. 5;
 Matches 6; Conservative 4; Mismatches 3; Indels 0; Gaps 0;

QY 2 KAMDPTPLWIKT 14
 | | | | | : : :
 Db 5 KSMGPAPRWMS 17

Note: The sequence data for this patent did not form part of the

```

RESULT 15
AAM75798
ID AAM75798 standard; Protein; 37 AA.
XX
AC AAM75798;
XX
DT 06-NOV-2001 (first entry)
XX
DE Human bone marrow expressed probe encoded protein SEQ ID NO: 36104.
XX
KW Human; bone marrow expressed exon; gene expression analysis; probe;
KW microarray; cancer; leukaemia; lymphoma; myeloma.
XX
OS Homo sapiens.
XX
PN WO200157276-A2.
XX
PD 09-AUG-2001.
XX
PF 30-JAN-2001; 2001WO-US00668.
XX
PR 04-FEB-2000; 2000US-0180312.
PR 26-MAY-2000; 2000US-0207456.
PR 30-JUN-2000; 2000US-0608408.
PR 03-AUG-2000; 2000US-0632366.
PR 21-SEP-2000; 2000US-0234687.
PR 27-SEP-2000; 2000US-0236359.
PR 04-OCT-2000; 2000GB-0024263.
XX
PA (MOLE-) MOLECULAR DYNAMICS INC.
XX
PI Penn SG, Hanzel DK, Chen W, Rank DR;
XX
DR WPI; 2001-488900/53.
XX
PT Human genome-derived single exon nucleic acid probes useful for
PT analyzing gene expression in human bone marrow -
XX
FS Example 4; SEQ ID NO: 36104; 658pp + Sequence Listing; English.
XX
CC The present invention provides a number of single exon nucleic acid
CC probes which are derived from genomic sequences expressed in the human
CC bone marrow. They can be used to measure gene expression in bone marrow
CC samples, which may enable the improved diagnosis and treatment of cancers
CC such as lymphoma, leukaemia and myeloma. The present sequence is a
CC protein encoded by one of the probes of the invention.
XX
SQ Sequence 37 AA;

Query Match 52.48; Score 44; DB 22; Length 37;
Best Local Similarity 46.28; Pred. No. 5;
Matches 6; Conservative 4; Mismatches 3; Indels 0; Gaps 0;

Qy 2 KAMDPTPLTIKT 14
Db 5 KSMGPAPPRWRS 17

Search completed: June 27, 2003, 18:01:23
Job time : 38 secs

```